Klaria signs exclusive development, license and supply agreement with Purdue Pharma (Canada) for acute treatment of opioid overdose (KL-00514)
Klaria AB and Purdue Pharma (Canada) today announce they have entered into exclusive development and license and supply agreements for KL-00514 (Naloxone Buccal Film). KL-00514 is a developmental stage formulation of naloxone intended for acute treatment of intentional or accidental opioid overdose designed to give a rapid and reliable response in patients while providing a compact dosage form that could be distributed widely to patients, caregivers and emergency personnel.KL-00514 will be co-developed by Klaria and Purdue Pharma (Canada). The development program will include formulation